Glenmark Pharmaceuticals Limited
GLENMARK
Kedudukan dalam Saham
#2740
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Harga Saham
$24.39
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$6.88B
Perubahan (1 hari)
-1.20%
Perubahan (1 tahun)
15.69%
Negara
IN
Perdagangan Glenmark Pharmaceuticals Limited (GLENMARK)
Kategori
Healthcare
Nisbah P/E bagi Glenmark Pharmaceuticals Limited (GLENMARK)
Nisbah P/E pada October 2026 TTM: 35.54
Menurut laporan kewangan dan harga saham terkini Glenmark Pharmaceuticals Limited, nisbah P/E semasa (TTM) ialah 35.54. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -18.46.
Sejarah nisbah P/E bagi Glenmark Pharmaceuticals Limited dari 2004 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 35.54 | -12.62% |
| 2025 | 40.67 | -320.32% |
| 2024 | -18.46 | -141.85% |
| 2023 | 44.11 | 233.08% |
| 2022 | 13.24 | -2.02% |
| 2021 | 13.52 | 80.58% |
| 2020 | 7.49 | -62.43% |
| 2019 | 19.92 | -0.14% |
| 2018 | 19.95 | -23.99% |
| 2017 | 26.25 | -17.43% |
| 2016 | 31.79 | -29.15% |
| 2015 | 44.87 | 58.83% |
| 2014 | 28.25 | 38.70% |
| 2013 | 20.37 | 12.07% |
| 2012 | 18.17 | 8.60% |
| 2011 | 16.73 | -20.90% |
| 2010 | 21.15 | 4.33% |
| 2009 | 20.28 | 7.15% |
| 2008 | 18.92 | -19.38% |
| 2007 | 23.47 | -44.77% |
| 2006 | 42.49 | 35.57% |
| 2005 | 31.35 | 57.81% |
| 2004 | 19.86 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -1.63% |
IN
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.